Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities
(2025 Version).
10.3779/j.issn.1009-3419.2025.102.01
- Author:
Jun CHEN
;
Baohui HAN
;
Yi HU
;
Jian HU
- Collective Name:Lung Cancer Specialty Committee of Chinese Elderly Health Care Association
- Publication Type:Consensus Development Conference
- Keywords:
Lung neoplasms;
MET abnormalities;
MET inhibitors;
Treatment
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Lung Neoplasms/drug therapy*;
Proto-Oncogene Proteins c-met/metabolism*;
Consensus;
Mutation
- From:
Chinese Journal of Lung Cancer
2025;28(2):81-94
- CountryChina
- Language:Chinese
-
Abstract:
The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, plays a crucial role in the regulation of physiological processes such as cell proliferation, migration, invasion, and angiogenesis. The MET gene is one of the key drivers in non-small cell lung cancer (NSCLC), with various forms of abnormalities including MET exon 14 (METex14) skipping mutations, MET gene amplification, MET fusions, MET protein overexpression, MET activating mutations and etc. With an increasing understanding of the mechanisms underlying MET abnormalities, therapeutic strategies targeting these abnormalities have gained significant attention, and numerous studies have confirmed that NSCLC patients with MET abnormalities can derive substantial benefits from such treatments. Lung Cancer Specialty Committee of Chinese Elderly Health Care Association organized a panel of experts to provide professional recommendations on current clinical issues in the diagnosis and treatment of MET-aberrant NSCLC, combining clinical practice experiences and evidence-based medical evidences. The "Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities (2025 Version)" has been formulated to provide standardized guidances for clinical practice in China, with the aim of optimizing the treatment outcomes.
.
